Results 61 to 70 of about 291 (138)
Cell-free DNA fragmentomics for preeclampsia risk assessment
Abstract Preeclampsia (PE) is a pregnancy-specific hypertensive disorder that could lead to serious maternal and fetal complications, yet early identification of women at risk remains challenging because reliable biomarkers are limited.
Wenqiu Xu +39 more
openaire +1 more source
Cell-Free DNA Fragmentomics: The New “Omics” on the Block [PDF]
Rossa W K Chiu +4 more
openaire +1 more source
Mechanistic Modeling of cfDNA Fragmentome Dynamics Predicts Progression to Immunotherapy
BackgroundPlasma cell-free DNA (cfDNA) shows promise as predictive cancer biomarker, but mechanisms governing cfDNA production/fragmentation/elimination dynamics, and their relationships with tumor burden and disease progression, remain poorly understood.
Boutonnet, Audrey +9 more
core +3 more sources
Analysis of cfDNA fragmentomics metrics and commercial targeted sequencing panels
Abstract Fragmentomics based analysis of cell-free DNA (cfDNA) has recently emerged as a method to infer epigenetic and transcriptional data. Many of these reports analyze whole genome sequencing (WGS) which is not readily available clinically. Targeted exon panels are used for clinical cfDNA variant calling.
Kyle T. Helzer +26 more
openaire +3 more sources
Leveraging cfDNA fragmentomic features for the early detection of colorectal cancer
Background Early detection of colorectal cancer (CRC) is crucial for improving patient outcomes. Cell-free DNA (cfDNA) analysis has emerged as a promising non-invasive approach for cancer detection. This study aims to develop a machine learning algorithm leveraging cfDNA fragmentomic features to accurately ...
Shan, Lina +11 more
openaire +2 more sources
Computational modeling approaches for circulating cellfree DNA in oncology
International audienceMany cancer patients undergoing immune-checkpoint inhibition (ICI) experience early progression (EP), defined as progression at the first imaging evaluation.
Nguyen Phuong, Linh
core +3 more sources
International audienceBackground: Immune-checkpoint inhibition (ICI) has significantly advanced cancer treatment, but many patients experience early progression (EP).
Boutonnet, Audrey +9 more
core +1 more source

